---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-070566"
form_type: "8-K"
ticker: "CUE"
cik: "0001645460"
company_name: "Cue Biopharma, Inc."
filed_at: "2024-06-07T23:59:59+00:00"
generated_at: "2026-06-01T05:36:08.930075+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Cue Biopharma appoints Michael J. Fox to board; grants 48,800-share option

## Summary
- Michael J. Fox appointed to Board and Compensation Committee effective June 5, 2024.
- Received option to purchase 48,800 shares vesting over three years (1/3 at one year, then quarterly).
- Stockholders elected all 7 director nominees; Passeri received 13,099,740 for, 765,119 withheld.
- Ratified RSM US LLP as auditor for FY2024 with 32,418,349 for, 1,635,231 against.
- Non-binding say-on-pay passed with 11,745,009 for, 1,924,707 against, 20,311,373 broker non-votes.

## SEC filing metadata
- accession: 0000950170-24-070566
- form_type: 8-K
- ticker: CUE
- cik: 0001645460
- company_name: Cue Biopharma, Inc.
- filed_at: 2024-06-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645460/000095017024070566/0000950170-24-070566-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645460/000095017024070566/cue-20240605.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-070566
- JSON: https://secwatch.observer/filing/0000950170-24-070566.json
- Plain text: https://secwatch.observer/filing/0000950170-24-070566.txt

## Key facts
- Executive change
  Michael J. Fox was appointed as Director at Cue Biopharma, Inc..
  - Action: appointed
  - Role: Director
  source text: On June 5, 2024, Michael J. Fox was appointed to the board of directors (the “Board”) and the Compensation Committee of the Board of Cue Biopharma, Inc. (the “Company”), following the recommendation of the Corporate Governance and Nominating Committee of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645460/000095017024070566/0000950170-24-070566-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.